Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.61 |
| ▸ | CCR2 | P41597 | 5/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.56 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.53 |
| ▸ | F10 | P00742 | 3/20 | 0.52 |
| ▸ | CCR9 | P51686 | 1/20 | 0.52 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241163 | 0.94 | PPARG (0.59) | PPARGCCR2SRD5A2LTB4RLTB4R2 | |
| SCHEMBL7247228 | 0.87 | PPARG (0.57) | PPARGCCR2SRD5A2LTB4RLTB4R2 | |
| SCHEMBL4198698 | 0.85 | CCR2 (0.71) | CCR2ABCB11CCR9 | |
| SCHEMBL4212911 | 0.85 | CCR2 (0.64) | CCR2ABCB11CCR9 | |
| SCHEMBL13802517 | 0.84 | SRD5A2 (0.60) | PPARGSRD5A2LTB4RLTB4R2PPARD | |
| SCHEMBL7458022 | 0.83 | CCR2 (0.52) | PPARGCCR2SRD5A2LTB4RLTB4R2 | |
| SCHEMBL4208025 | 0.82 | CCR2 (0.74) | PPARGCCR2ABCB11CCR9GPR35 | |
| SCHEMBL3967516 | 0.80 | CCR2 (0.73) | PPARGCCR2SRD5A2LTB4RLTB4R2 | |
| SCHEMBL4201841 | 0.80 | CCR2 (0.77) | CCR2ABCB11CCR9 | |
| SCHEMBL700511 | 0.80 | SRD5A2 (0.73) | CCR2SRD5A2LTB4RLTB4R2PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PPARG 1385/4885CCR2 1386/4885SRD5A2 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.